StockData
MapLight Therapeutics, Inc. logo

MapLight Therapeutics, Inc. (MPLT) stock

MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$6.65+0.08 (+1.22%)

Close on Nov 18, 2026Market cap $308.41MP/E –Yield –

MapLight Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

MapLight Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$242.93M. For fiscal 2025 it was -$169.08M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$169.08M–
FY2024Dec 31, 2024-$82.95M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$63.55M–
Q1 FY2026Mar 31, 2026-$64.50M–
Q4 FY2025Dec 31, 2025-$83.38M–
Q3 FY2025Sep 30, 2025-$31.50M–
Q2 FY2025Jun 30, 2025-$30.66M–
Q1 FY2025Mar 31, 2025-$23.54M–
Q4 FY2024Dec 31, 2024-$22.78M–
Q3 FY2024Sep 30, 2024-$20.89M–

More MapLight Therapeutics figures

See a number that looks wrong?